• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Tuesday, June 6, 2023
Midland County News Online
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
No Result
View All Result
Home News

U.S. FDA Approves New Bristol Myers Cancer Immunotherapy – Reuters.com

us-fda-approves-new-bristol-myers-cancer-immunotherapy-–-reuters.com
Share on FacebookShare on Twitter

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly

Register now for FREE unlimited access to Reuters.com

March 18 (Reuters) – Bristol Myers Squibb Co (BMY.N) said on Friday that U.S. regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest form of skin cancer.

The company said it expects the treatment to eventually garner annual sales of more than $4 billion.

The U.S. Food and Drug Administration approved relatlimab from a class known as LAG-3 inhibitors – short for lymphocyte-activation gene 3 – for use in combination with Bristol’s blockbuster immunotherapy Opdivo as an initial treatment for advanced melanoma.

Register now for FREE unlimited access to Reuters.com

Relatlimab, which will be sold under the brand name Opdualag, more than doubled the time it took for advanced melanoma to worsen compared with Opdivo alone in clinical trials, a measure known as progression-free survival.

The medicine is Bristol Myers’ third approved cancer immunotherapy – drugs that enlist the body’s defenses in the fight against tumors. Opdivo targets a protein called PD-1. Yervoy, the drugmaker’s first such drug, is a CTLA-4 inhibitor.

Relatlimab will only be used in combination with Opdivo, Chief Medical Officer Samit Hirawat said in an interview.

Hirawat said LAG-3 inhibitors like relatlimab can reinvigorate the immune system by restoring the function of “exhausted” T cells – a key component of the immune system – which could improve Opdivo’s performance.

“Our hypothesis is that the best applicability of a LAG-3 inhibitor will be in combination with a PD-1 inhibitor” like Opdivo, he said.

The company expects to charge $27,389 for the combination.

Bristol Myers said it expects the combination therapy to generate sales in excess of $4 billion a year by 2029.

Bristol Myers is testing the combination of Opdivo and relatlimab in other tumor types including colorectal, lung and kidney cancer.

Register now for FREE unlimited access to Reuters.com

Reporting by Michael Erman; Additional reporting by Akriti Sharma in Bengaluru; Editing by Bill Berkrot and Leslie Adler

Our Standards: The Thomson Reuters Trust Principles.

Midland County News Online

© 2021 Midland County News Online

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 Midland County News Online

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT